S&P 500 Industrials Sector SEC Filings — May 06, 2026

06-05-2026

PARKE BANCORP, INC. reported robust Q1 2026 financial results with net income of $11,844 thousand (up 52% YoY from $7,778 thousand), driven by net interest income growth of 33% to $22,132 thousand and a reduced provision for credit losses to $202 thousand from $590 thousand. However, total assets contracted 2% QoQ to $2,212,935 thousand, reflecting a 29% decline in cash and cash equivalents to $110,874 thousand and a 3% drop in total deposits to $1,698,744 thousand, while noninterest-bearing deposits fell 16% QoQ. Shareholders' equity increased 3% QoQ to $335,563 thousand supported by earnings retention despite common stock dividends of $2,119 thousand.

• ·Basic EPS $1.01 vs $0.66 YoY; Diluted EPS $0.99 vs $0.65 YoY
• ·Common stock dividend $0.18 per share ($2,119 thousand total); Preferred dividend $15.00 per share ($5 thousand total)
• ·Gross loans increased 0.4% QoQ to $2,043,296 thousand
• ·Non-interest expense increased 10% YoY to $7,214 thousand, with compensation up 13% to $3,704 thousand
• ·Cash flow from operating activities $13,019 thousand vs $6,999 thousand YoY
• ·Net cash used in financing activities $50,799 thousand, driven by deposit outflows

06-05-2026

Mirum Pharmaceuticals reported product sales revenue of $159,882 thousand for Q1 2026, up 43% YoY from $111,585 thousand, reflecting strong commercial performance. However, net loss ballooned to $790,155 thousand from $14,677 thousand YoY, driven by $726,302 thousand in acquired in-process R&D expenses related to an asset acquisition, leading to operating expenses surging to $949,347 thousand. Cash and equivalents rose to $324,907 thousand QoQ, bolstered by $270,079 thousand in financing proceeds, though stockholders' equity declined to $242,494 thousand amid significant share dilution.

• ·Accounts receivable increased to $133,113 thousand as of March 31, 2026 from $123,330 thousand as of December 31, 2025.
• ·Research and development expenses rose to $97,910 thousand in Q1 2026 from $41,044 thousand YoY.
• ·Selling, general and administrative expenses increased to $96,330 thousand in Q1 2026 from $57,706 thousand YoY.
• ·Net cash used in investing activities was $11,569 thousand in Q1 2026, relatively flat YoY.
• ·Holdback liabilities recorded at $74,057 thousand total ($25,800 thousand current, $48,257 thousand noncurrent) related to asset acquisition.

06-05-2026

Pattern Group Inc. reported record Q1 2026 revenues of $774 million, up 43% YoY from $540 million, with record NRR of 127% (up from 115%), non-Amazon revenue of $71 million (+119% YoY), and international revenue of $90 million (+101% YoY). Net income increased 28% to $29 million, though diluted EPS was slightly down to $0.16 from $0.17 YoY due to higher share count; Adjusted EBITDA rose 59% to $54 million. The company raised FY2026 guidance to $3.29-$3.33 billion in revenue (32-33% YoY growth) and $199-$201 million in Adjusted EBITDA (30-32% YoY growth), with Q2 outlook of $810-$820 million revenue (35-37% YoY) and $45-$46 million Adjusted EBITDA (30-33% YoY).

• ·Q1 2026 operating cash flow of $73 million, up 50% YoY from $48 million.
• ·Cash and cash equivalents increased to $344 million as of March 31, 2026 from $289 million at Dec 31, 2025.
• ·Accounts receivable decreased to $141 million from $177 million YoY.
• ·Weighted-average diluted shares outstanding increased to 179,458 from 90,591 YoY.
• ·Conference call scheduled for May 6, 2026 at 3:00 p.m. Mountain Time.

06-05-2026

LandBridge reported first quarter 2026 revenues of $51.0 million, up 16% YoY from $44.0 million but down sequentially from $56.8 million in Q4 2025 due to seasonality across segments including surface use royalties (-6% QoQ), resource sales (-9% QoQ), and oil & gas royalties (-5% QoQ). Adjusted EBITDA rose 16% YoY to $44.9 million with margins at 88%, cash from operations surged 158% YoY to $41.1 million, and the company raised full-year 2026 Adjusted EBITDA guidance to $210-230 million while acquiring ~5,700 acres and declaring a $0.12 per share dividend. Strong YoY growth and commercial momentum were offset by QoQ declines and segment softness.

• ·Capital expenditures for Q1 2026 were $0.2 million; net cash used in investing activities was $2.1 million.
• ·Net cash used in financing activities was $40.0 million, including $14.7 million dividends/distributions and $25.2 million debt repayments.
• ·Borrowings reduced to $545 million from $570 million as of Dec 31, 2025.
• ·Dividend of $0.12 per Class A share payable June 18, 2026 to shareholders of record June 4, 2026.
• ·Available borrowing capacity under revolving credit facility: $230.0 million.

06-05-2026

Advantage Solutions Inc. reported Q1 2026 revenues of $869,601 thousand, up 5.8% YoY from $821,792 thousand, with strong growth in Experiential Services (+22.9%) and modest gains in Retailer Services (+4.3%), but Branded Services revenues declined 11.3% YoY amid sharp drops in branded merchandising (-26.7%) and omni-commerce marketing services (-31.1%). Operating income improved to $4,162 thousand profit from a $14,621 thousand loss, and cash from operations turned positive at $23,728 thousand versus a $39,627 thousand outflow; however, net loss widened to $71,831 thousand from $56,130 thousand due to higher interest, other expenses, and income taxes. Total cash and equivalents fell to $143,870 thousand QoQ from $240,850 thousand, while long-term debt decreased to $1,520,790 thousand from $1,660,611 thousand.

• ·Investments in unconsolidated affiliates decreased to $205,336 thousand from $234,138 thousand QoQ.
• ·Other intangible assets, net declined to $951,593 thousand from $993,927 thousand QoQ.
• ·Proceeds from divestitures of $40,919 thousand in investing activities.
• ·Principal payments on long-term debt of $131,319 thousand in financing activities.

06-05-2026

InMed Pharmaceuticals Inc. reported total assets of $9,133,806 as of March 31, 2026, down 41% from $15,580,040 at June 30, 2025, driven by a decline in cash and cash equivalents to $5,158,932 from $10,743,430 amid ongoing cash burn. For the nine months ended March 31, 2026, net loss from continuing operations improved 4.8% to $6,530,079 from $6,855,692, with slightly lower operating cash use of $5,678,995 versus $5,988,445; however, total net loss widened to $6,721,458 from $6,373,822 due to a shift to losses in discontinued BayMedica operations ($191,379 loss vs. $481,870 income). The company is winding down its BayMedica commercial business segment due to U.S. legislation impacting inventory of rare, non-intoxicating cannabinoids, reflected in higher discontinued liabilities including $531,136 severance.

• ·Common shares outstanding increased to 3,314,063 as of March 31, 2026 from 2,002,186 at June 30, 2025.
• ·Current assets of discontinued operations declined to $1,070,313 from $1,760,918, with inventories down to $541,135 from $961,173.
• ·Proceeds from private placement and SEPA in nine months ended March 31, 2026 totaled $231,675, down significantly from $4,361,220 prior year.
• ·Research and development expenses for nine months ended March 31, 2026 at $2,222,732, slightly down from $2,243,948 (flat).

06-05-2026

SandRidge Energy reported Q1 2026 financial results with total revenues of $49.8 million, up 17% YoY, driven by 31% higher oil production and 4% increase in total production to 18.6 MBoe/d; net income rose to $18.7 million from $13.0 million YoY, and Adjusted EBITDA reached $33.7 million, up from $25.5 million. The Board increased the ongoing quarterly dividend by 8% to $0.13 per share and declared a one-time $0.20 per share dividend, payable June 1, 2026. However, production declined 7% QoQ to 18.6 MBoe/d from 19.5 MBoe/d, impacted by NGL recovery issues and Winter Storm Fern, while free cash flow turned negative at $(1.1) million versus positive $13.6 million YoY.

• ·Lease operating expense (LOE) $10.8 million or $6.45 per Boe in Q1 2026, down from $6.79 per Boe YoY.
• ·No outstanding debt as of March 31, 2026; cash decreased QoQ to $104.1 million from $112.3 million.
• ·Adjusted G&A $2.4 million or $1.42 per Boe in Q1 2026.
• ·Hedging includes oil fixed price swaps for 799 Bbl/d at $74.37 through Dec 2026.
• ·Over four years without a recordable safety incident.

06-05-2026

Edgewell Personal Care reported Q2 FY26 net sales of $519.5 million from continuing operations, up 0.6% YoY due to currency but organic sales down 2.4%, with Wet Shave up 3.0% reported (organic -0.7%) while Sun and Skin Care declined 2.5% (organic -4.5%). Adjusted EPS fell to $0.60 from $0.69 and adjusted EBITDA to $73.8 million from $84.7 million, though results exceeded expectations; gross margin dropped 410 basis points to 41.8%. The company reaffirmed most FY26 outlook but lowered GAAP EPS guidance to flat to $0.40 and raised expected restructuring charges to $90 million, while returning $22.9 million to shareholders via dividends and repurchases.

• ·Adjusted net debt leverage ratio of 4.0x as of Q2 FY26 end.
• ·FY26 outlook: Organic net sales -1.0% to +2.0%; Adjusted EPS $1.70-$2.10; Adjusted EBITDA $245-$265M; Adjusted free cash flow $80-$110M; Adjusted net debt leverage 3.3x-3.5x at FY end.
• ·Q2 dividend declared $0.15 per share, payable July 9, 2026.
• ·Productivity savings of 220 basis points offset by 420 bps inflation/tariffs, 70 bps unfavorable mix/promos, 40 bps currency.

06-05-2026

Immunocore reported Q1 2026 KIMMTRAK net product sales of $106.7 million, up 14% YoY from $93.9 million, driven by 19.1% US growth to $67.4 million and 4.9% Europe growth to $34.4 million, with net income rising to $13.0 million from $5.0 million. However, R&D expenses increased to $61.1 million from $56.5 million due to Phase 3 trial progression, while SG&A expenses decreased to $37.9 million from $40.2 million. Cash and equivalents stood at $845 million as of March 31, 2026, supporting pipeline advancement including PRISM-MEL-301 and TEBE-AM trials.

• ·KIMMTRAK approved in 39 countries, launched in over 30.
• ·Phase 3 AACR data: 5-year OS 16% vs 8% control (HR 0.67), median OS 21.6 vs 16.9 months.
• ·TEBE-AM Phase 3 enrollment completion expected H1 2026, topline H2 2026.
• ·PRISM-MEL-301 Phase 3 ongoing for first-line advanced cutaneous melanoma.
• ·Potential patient populations: 4,000 for 2L+ CM, 1,200 adjuvant uveal melanoma, 10,000 first-line CM.
• ·CTA filed for IMC-S118AI Dec 2025, Phase 1 H1 2026.
• ·ASCO 2026 posters on May 30 and May 31.

06-05-2026

Marriott International reported Q1 2026 results with worldwide RevPAR up 4.2% YoY (constant $), Adjusted EBITDA increasing 15% to $1,398 million, Adjusted diluted EPS of $2.72 (up from $2.32), and net rooms growth of 4.5% YoY after adding 15,900 rooms. However, reported net income fell 3% to $648 million from $665 million due to higher taxes ($210 million vs. $99 million) and interest expense ($204 million vs. $183 million), while Middle East RevPAR declined amid conflict, partially offsetting EMEA's 3% growth. The development pipeline hit a record 618,000 rooms, and the company repurchased 2.1 million shares for $0.7 billion.

• ·Pipeline includes 43% rooms under construction; over half of pipeline rooms in international markets.
• ·Issued $600M Series WW Senior Notes due 2033 (4.5% coupon) and $850M Series XX Senior Notes due 2038 (5.1% coupon) in Q1 2026.
• ·Q2 2026 outlook: Comparable systemwide constant $ RevPAR growth 1.5% to 2.5%; full year 2.0% to 3.0%.
• ·Full year 2026 net rooms growth outlook: 4.5% to 5%.
• ·Year-to-date through April 29, 2026: Returned over $1.2B to shareholders; repurchased 3.1M shares for $1.1B.

06-05-2026

NewAmsterdam Pharma Company N.V. has issued a proxy statement for its Annual General Meeting on June 2, 2026, seeking shareholder approval for adoption of the Dutch statutory annual accounts for FY ended December 31, 2025, discharge of director liability, reappointment of Deloitte Accountants B.V. as auditor, reappointment of non-executive directors John W. Smither and Janneke van der Kamp, extensions of share issuance authorizations, approval of the 2026 Employee Stock Purchase Plan, and a non-binding advisory vote on 2025 named executive officer compensation. The record date is May 5, 2026, with attendance notices and proxies due by 11:59 p.m. ET on May 31, 2026. No specific financial performance metrics or period-over-period comparisons are disclosed in the provided filing content.

• ·Annual General Meeting location: offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, Netherlands at 5:00 p.m. CEST on June 2, 2026.
• ·Dutch statutory board report and annual accounts for FY 2025 available no later than May 18, 2026 on company website.
• ·Proxy submission options: toll-free telephone (1-800-690-6903), www.proxyvote.com, or mail.

06-05-2026

Myriad Genetics reported Q1 2026 revenue of $200.4M, up 2.3% YoY from $195.9M, driven by strong growth in Mental Health (+23.5%) and Cancer Care Continuum (+4.0%), though offset by a 15.0% decline in Prenatal Health. Gross profit rose 2.6% to $137.6M, but operating expenses increased 3.1% to $168.3M including $5.4M in impairment charges, resulting in a wider operating loss of $30.7M (vs $29.0M) and net loss of $34.1M (vs $0.1M). Cash and equivalents decreased to $124.4M from $149.6M at year-end, with stockholders' equity falling to $337.4M.

• ·Net cash used in operating activities improved slightly to $15.7M from $16.3M YoY.
• ·Total assets decreased to $673.7M from $706.6M at December 31, 2025.
• ·Long-term debt stable at $120.3M.
• ·Stock-based compensation expense $6.5M in Q1 2026 vs $9.5M in Q1 2025.

06-05-2026

Deluxe reported Q1 2026 revenue of $538.1 million, up 0.3% YoY on reported basis but 2.7% on comparable adjusted basis, driven by strong growth in Data Solutions (+26.3% to $97.5 million) and Merchant Services (+7.2% to $104.9 million); however, the Print segment declined 10.0% YoY to $262.2 million. Comparable adjusted EBITDA rose 19.7% to $117.9 million with margin expansion to 21.9%, net income improved to $35.8 million from $14.0 million, and total debt was reduced by $32.3 million. The company updated full-year 2026 outlook post-Safeguard divestiture, expecting revenue of $1.985-$2.050 billion (-1% to +2% comparable adjusted growth) and free cash flow of ~$200 million (+14% vs 2025).

• ·Quarterly dividend of $0.30 per share, payable June 2, 2026 to shareholders of record May 19, 2026.
• ·FY 2026 adjusted EBITDA outlook: $430-$455 million (+4% to +10% comparable adjusted growth).
• ·FY 2026 adjusted diluted EPS outlook: $3.60-$4.00 (+9% to +21% comparable adjusted growth).
• ·Data Solutions adjusted EBITDA margin declined to 23.4% from 25.5% YoY.
• ·Print adjusted EBITDA declined to $85.7 million from $90.8 million YoY.

06-05-2026

Next Bridge Hydrocarbons, Inc. filed an S-1/A registration statement on May 6, 2026, for its IPO, disclosing oil and gas leasehold interests totaling 2,838 gross acres (2,229 net) across Texas Hazel Project, Oklahoma Viking properties, and Louisiana Wildcat projects as of December 31, 2025. Investments in properties rose sharply to $4,803,655 in 2025 from $1,692,885 in 2024, driven by $4,803,655 in development costs. However, production revenue fell 17.8% YoY to $10,343, with oil volumes down 14% to 86 Bbls and gas down 30% to 2,441 Mcf from Oklahoma properties, no revenue from Hazel, one dry hole drilled, no proved reserves, and full $5,373,207 impairment of unevaluated costs.

• ·No proved reserves (0 Bbls oil, 0 Mcf gas, 0 BOE) as of Dec 31, 2025 and 2024.
• ·Company has no employees and relies on independent consultants and contractors.
• ·Average production cost $20.12 per BOE in 2025 vs $272.34 in 2024 (significant decline).
• ·No production revenue from Hazel Project in 2025 or 2024 due to option agreement terms.
• ·Hazel Project: 806 gross acres (645 net), all developed.
• ·Oklahoma Viking: 640 gross acres (192 net), all developed.
• ·Louisiana Wildcat: 1,392 gross/net acres, all undeveloped.

06-05-2026

Prime Capital Management Co Ltd, based in Hong Kong, filed its 13F-HR report on May 6, 2026, for the quarter ended March 31, 2026, disclosing 7 equity holdings all with sole voting and disposition power. The portfolio features significant positions in technology stocks including NVIDIA Corporation ($154200818, 884179 shares), Tesla Inc ($267608327, 719861 shares), and Taiwan Semiconductor Mfg Ltd ($224333914, 663808 shares). Other holdings include Cava Group Inc ($83458867, 1031630 shares), Micron Technology Inc ($85344465, 252618 shares), E L F Beauty Inc ($36640866, 604535 shares), and Kinsale Cap Group Inc ($39461047, 115498 shares).

• ·All holdings reported with sole shared voting power, sole shared disposition power, and no other powers.
• ·Filer CIK: 0001448793
• ·SEC file number: 028-14988
• ·Business address: Unit 2303 Low Block Grand Millennium Plz, 181 Queen's Road Central, Hong Kong

06-05-2026

Barrel Energy Inc. dismissed Fruci & Associates II, PLLC as its independent registered public accounting firm on April 28, 2026, following their audits of fiscal years 2023 and 2024 and review of financials through September 30, 2025. The Company engaged Shah Teelani & Associates Chartered Accountants on April 21, 2026, to audit the fiscal year ended December 31, 2025. No disagreements on accounting principles, financial disclosures, auditing scope, or reportable events occurred with the prior auditor.

• ·Previous auditor provided services for Form 10 filed February 23, 2026.
• ·Letter from Fruci & Associates II, PLLC to be filed by amendment as Exhibit 16.1.
• ·Company address: 3859 S Valley View Blvd, Ste 2 #107, Las Vegas, NV 89103.

06-05-2026

Shengqi Capital (Hong Kong) Ltd filed its quarterly 13F-HR on May 6, 2026, disclosing equity holdings as of March 31, 2026, with a total portfolio value of approximately $40.9 million. The largest position is 100 shares of Alphabet Inc Class C stock valued at $28.686 million, followed by 200 shares of ProShares UltraPro QQQ valued at $8.336 million, 100 shares of iShares Bitcoin Trust ETF valued at $3.842 million, and 100 shares of Greenland Mines Ltd valued at $0.033 million. No prior period comparisons are provided in the filing.

• ·Filing signed by Lau Ka Chun on April 14, 2026
• ·All holdings reported as sole voting power with no shared voting, puts/calls, or other managers
• ·Company address: Room 1805, 90 Connaught Rd Central, Sheung Wan, Hong Kong

06-05-2026

On May 5, 2026, Patriot National Bancorp, Inc. posted a presentation on its Investor Relations website containing certain Q1 2026 financial information for its wholly owned subsidiary, Patriot Bank, National Association. The presentation is furnished as Exhibit 99.1 under Items 7.01 and 9.01 of this Form 8-K. This disclosure is made pursuant to Regulation FD and is not deemed 'filed' for purposes of the Exchange Act.

• ·Investor Relations website: https://bankpatriot.com/Learn/About/Investor-Relations
• ·Filing pertains to Q1 2026 financial information

06-05-2026

TopTier Wealth Management, LLC filed its 13F-HR report on May 6, 2026, disclosing 795 equity positions valued at $162660122 as of March 31, 2026, all held with sole voting and dispositive power. Largest holdings include Invesco QQQ Trust at $10480313 (18158 shares), WisdomTree US SmallCap Fund at $5498932 (94730 shares), and State Street SPDR S&P 500 ETF at $4756097 (7313 shares). No changes or performance metrics relative to prior periods are reported in this snapshot filing.

• ·Report filed as of May 6, 2026, for period ending March 31, 2026.
• ·No other investment managers included (0 reported).
• ·All positions listed as SH SOLE with 0 shared, 0 other voting power.

06-05-2026

My Portfolio Guide, LLC reported 166 equity holdings totaling $180,815,716 as of March 31, 2026, in its quarterly 13F-HR filing. The portfolio features heavy allocations to SPDR ETFs (e.g., $29.4M, $16.3M positions), gold/miners trusts ($18.8M), First Trust funds ($11.5M), and individual stocks like Apple Inc ($7.1M). All positions are held with sole voting and sole dispositive power; no prior period comparisons are available.

• ·Filing date: May 6, 2026
• ·Report period end: March 31, 2026
• ·Business address: 3020 Old Ranch Parkway, Suite 300, Seal Beach, CA 90740
• ·All holdings with sole voting power (SH SOLE) and no shared power indicated

06-05-2026

Standex International Corp reported robust Q3 FY2026 results with net sales increasing 8% YoY to $224,595 thousand, gross profit up 12% to $91,932 thousand, and net income attributable to common stockholders surging to $66,978 thousand from $21,880 thousand, driven by a $56,837 thousand gain on sale of business; nine-month sales rose 17% YoY to $663,346 thousand with net income to $84,155 thousand. However, total assets declined 3% to $1,526,777 thousand from $1,566,880 thousand at June 30, 2025, goodwill fell 4% to $585,503 thousand, inventories remained flat at $129,563 thousand, and other comprehensive loss included $39,427 thousand in foreign currency translation losses for the nine months.

• ·Diluted EPS total for three months ended March 31, 2026: $5.55 (up from $1.81 YoY)
• ·Diluted EPS total for nine months ended March 31, 2026: $6.98 (up from $3.41 YoY)
• ·Restructuring costs three months: $2,989 thousand (up from $1,976 thousand YoY)
• ·Weighted average diluted shares three months March 31, 2026: 12,062 thousand
• ·Dividends declared nine months: $1.00 per share ($12,030 thousand total)

06-05-2026

Shepherd Wealth Management Ltd Liability Co filed a 13F-HR report disclosing total holdings valued at $133,511,272 across 52 positions as of March 31, 2026. Top holdings include iShares 1-3 Year Treasury Bond ETF ($27,527,415), State Street SPDR S&P 500 ETF Trust ($21,337,673), and iShares 20+ Year Treasury Bond ETF ($18,443,459). Other significant positions feature NVIDIA Corporation ($4,554,587), Invesco QQQ Trust ($11,222,314), and Health Care Select Sector SPDR Fund ($9,941,859).

• ·Filing submitted on May 6, 2026, for period ending March 31, 2026
• ·All positions reported as sole discretionary with no voting or other authority changes indicated
• ·Additional notable holdings: Tesla Inc ($2,823,588), Palantir Technologies Inc ($2,923,563), Apple Inc ($1,388,092)

06-05-2026

HighMark Wealth Management LLC filed Form 13F-HR on May 6, 2026, reporting its U.S. equity holdings as of March 31, 2026, with no additions, reductions, or other changes indicated across all positions. The portfolio is heavily weighted toward healthcare stocks, including top holdings Axogen Inc (value 11427862), Centessa Pharmaceuticals PLC (9405100), and Anaptysbio Inc (5216013). Other significant positions include Apple Inc (1989756), Eli Lilly & Co (1589362), and a diversified mix of technology, ETFs, and other sectors.

• ·Report period end: 2026-03-31
• ·Filing date: 2026-05-06
• ·All positions reported as SH SOLE with zero values in change columns (no buys, sells, or other adjustments)
• ·Adviser CRD number: 164790
• ·Filer CIK: 0001802451
• ·Business address: 944 Inwood Avenue N., St. Paul, MN 55128

06-05-2026

Blackstone Mortgage Trust, Inc. entered into a purchase agreement on May 5, 2026, to issue and sell $450 million aggregate principal amount of 6.250% Senior Secured Notes due 2031 in a private offering to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S. The Notes, issued at 100.000% of par value with semi-annual interest payments commencing December 1, 2026, are expected to close on May 19, 2026, subject to customary conditions, with net proceeds used for general corporate purposes including paying down existing secured indebtedness. No declines or flat metrics reported in this financing announcement.

• ·Notes fully and unconditionally guaranteed on an unsubordinated secured basis by certain subsidiaries.
• ·Interest payable semi-annually on June 1 and December 1, maturing June 1, 2031.
• ·Certain Initial Purchasers or affiliates may receive portion of proceeds to repay outstanding indebtedness.

06-05-2026

Corebridge Financial discussed its proposed merger with Equitable Holdings, Inc., highlighting complementary product suites, no apprehension from distribution partners, and expected expense synergies alongside revenue opportunities like $100B in assets to AllianceBernstein and $30B upside in wealth management cross-sell/upsell. Management plans share repurchases post-shareholder vote in December and deployment of remaining capital via accelerated share repurchase post-close, with pro forma guidance of $4B cash and $5B earnings implying ~80% free cash flow conversion. However, Individual Retirement sales were roughly flat YoY, suggesting tempered industry flows.

• ·No dis-synergies identified from merger; distribution partner overlap de minimis.
• ·Shareholder vote expected December 2026; Investor Day planned first half 2027 for detailed synergy guidance.
• ·BDC debt exposure features conservative leverage, low LTVs, high diversification, and solid investment grade ratings with no equity exposure.
• ·AI focus on front-end distribution enablement and back-end servicing (e.g., digital agents for group retirement plans).

06-05-2026

BML Capital Management, LLC filed a 13F-HR report disclosing total holdings of $155,765,709 across 16 positions as of March 31, 2026, primarily concentrated in biotechnology and pharmaceutical companies. Top holdings include Aclarís Therapeutics Inc ($53,437,500, 14,250,000 shares), Atea Pharmaceuticals Inc ($37,975,575, 7,058,657 shares), and Oramed Pharmaceuticals Inc ($10,768,585, 3,167,231 shares). Other notable positions are in Outset Medical Inc ($7,304,452), Tilly's Inc ($8,707,500), and a small Walmart Inc put option position valued at $329,138.

• ·All positions held with sole voting and investment discretion (SH SOLE).
• ·Report filed on May 6, 2026, for period ending March 31, 2026.
• ·BML Capital Management, LLC based in Zionsville, IN.

06-05-2026

GEO Group reported Q1 2026 revenues of $705.2 million, up 17% YoY from $604.6 million, with net income attributable to GEO operations surging 96% to $38.3 million and Adjusted EBITDA rising 32% to $131.4 million. The company repurchased 3.6 million shares for $50 million and raised FY2026 guidance to $2.95-$3.10 billion in revenues, $153-$166 million in net income ($1.15-$1.25 per diluted share), and $525-$545 million in Adjusted EBITDA. Strong growth stemmed from $520 million in new 2025 contracts, though ISAP saw a shift with GPS participants rising to 48,000 from 17,000 while SmartLINK users declined to 131,000 from 159,000.

• ·Q2 2026 guidance: revenues $715-$725M, net income $33-$39M ($0.25-$0.29 per diluted share), Adjusted EBITDA $130-$135M.
• ·FY2026 capex guidance: $137.5-$162.5M.
• ·Net leverage below 3.2x trailing 12 months Adjusted EBITDA.
• ·Share repurchase program: $359M remaining authorization.
• ·New Florida contracts transition July 1, 2026: Graceville (1,884 beds), Bay (985 beds).
• ·Reactivated facilities: Adelanto ICE Processing Center (CA), plus NJ, MI, GA, FL.
• ·Conference call: May 6, 2026 at 11:00 AM ET.

06-05-2026

Paradigm Capital Management, LLC/NV filed a 13F-HR disclosing 59 equity positions with a total market value of $109,127,000 as of March 31, 2026. The largest holding is J P MORGAN EXCHANGE TRADED F ULTRA SHRT ETF valued at $13,445,000 (265,661 shares), followed by VANGUARD SPECIALIZED FUNDS DIV APP ETF at $12,700,000 (59,053 shares) and VANGUARD WHITEHALL FDS HIGH DIV YLD at $9,244,000 (62,420 shares). No period-over-period changes are available in this filing.

• ·Filing date: May 06, 2026
• ·Report period end: March 31, 2026
• ·Filer address: 6170 Ridgeview Court, Suite F, Reno, NV 89519
• ·All holdings reported as sole investment discretion (SH SOLE)

06-05-2026

Caldwell Sutter Capital, Inc. filed its 13F-HR on May 6, 2026, disclosing equity holdings as of March 31, 2026, with a total portfolio value of $245,896,270 across 894 positions, all held with sole voting and investment discretion. The portfolio includes a diverse mix of common stocks, ETFs, sponsored ADRs, and physical commodity shares such as gold and silver. No prior period comparisons or changes in holdings are detailed in the filing.

• ·All positions reported with sole voting authority (SH SOLE) and no other managers.
• ·Company address: PO BOX 190, Sausalito CA 94966-0190; Business phone: 415-367-4982.
• ·Fiscal year end: September 30; State of incorporation: CA.

06-05-2026

Gallacher Capital Management LLC filed its 13F-HR on May 6, 2026, disclosing 301 equity positions held solely as of March 31, 2026. The portfolio is heavily weighted toward ETFs including JP Morgan and iShares products, with individual stocks such as PepsiCo Inc. ($15.92B, largest holding), Berkshire Hathaway ($5.06B), and Broadcom ($1.07B). No prior period data is provided in the filing, precluding period-over-period comparisons.

• ·Filer address: 10465 Park Meadows Drive #107, Lone Tree, CO 80124
• ·All positions reported as SH SOLE with full voting power (no shared or other managers indicated)

06-05-2026

Ultragenyx reported Q1 2026 total revenues of $136M, slightly down 2% YoY from $139M, with product sales at $89M (-2% YoY) and royalty revenue at $47M (-2% YoY). Operating expenses rose 8% YoY to $305M, driven by a 13% increase in R&D to $187M, resulting in a widened net loss of $185M (-23% YoY worse than $151M) and EPS of ($1.84). Cash and equivalents dropped sharply to $175M as of March 31, 2026 from $421M at year-end 2025, with net cash used in operations increasing to $197M from $166M YoY.

• ·Stockholders’ equity deficit worsened to ($236M) at Mar 31 2026 from ($80M) at Dec 31 2025.
• ·Total liabilities decreased slightly to $1,525M from $1,605M QoQ.
• ·Stock-based compensation expense was $30M in Q1 2026 vs $40M in Q1 2025.

06-05-2026

Gould Asset Management LLC /CA/ filed its 13F-HR disclosing holdings of $575,715,544 across 171 positions as of March 31, 2026. The largest position is SPDR S&P 500 ETF (TR Unit) valued at $145,245,752, representing over 25% of the portfolio, followed by iShares 0-5 Year TIPS Bond ETF at $48,583,358 and Vanguard Short Term Treasury ETF at $35,606,861. Other notable holdings include Apple Inc. at $10,283,414 and a diversified mix of ETFs and equities with no reported changes or performance metrics.

• ·Filing date: May 6, 2026
• ·Report period end: March 31, 2026
• ·All holdings reported as sole voting authority
• ·Heavy allocation to fixed income and broad market ETFs

06-05-2026

HughesLittle Investment Management Ltd. filed its 13F-HR report on May 6, 2026, for the quarter ended March 31, 2026, disclosing 14 equity positions with a total market value of $510815515. Key holdings include Brookfield Corp CL A LTD VT SH (1,541,385 shares valued at $62334365), Uber Technologies Inc (730,133 shares valued at $52518467), and Schwab Charles Corp (703,529 shares valued at $66117655). All positions are held with sole voting authority.

• ·Report filed as of May 6, 2026; period end March 31, 2026
• ·All 14 positions held with sole discretionary voting authority
• ·Firm located at 19 710-688 West Hastings Street, Vancouver, British Columbia, Canada V6B 1P1

06-05-2026

AMD reported strong Q1 FY2026 results with net revenue surging 38% YoY to $10,253 million from $7,438 million, gross profit up 45% to $5,416 million, operating income up 83% to $1,476 million, and net income nearly doubling 95% to $1,383 million. Diluted EPS rose to $0.84 from $0.44. However, operating expenses increased 34% YoY to $3,940 million driven by higher R&D (up 39%) and inventories grew 2% QoQ to $8,045 million.

• ·Cash flows from operating activities surged 215% YoY to $2,955 million.
• ·Total current assets increased to $28,628 million from $26,947 million QoQ.
• ·Long-term debt stable at $2,350 million.
• ·Stock repurchases totaled $221 million in Q1 FY2026.

06-05-2026

QuidelOrtho Corp reported total revenues of $619.8M for Q1 FY2026, down 10.5% YoY from $692.8M, driven by sharp declines in Point of Care (-34.0% to $112.8M) and Donor Screening (-39.1% to $7.8M), while Immunohematology grew 7.6% to $138.3M and Labs dipped 5.3% to $353.1M. Net loss widened to $91.8M from $12.7M YoY, with operating loss of $31.8M versus $32.6M income, and higher interest expense of $51.1M. Cash and equivalents fell to $140.4M from $169.8M QoQ amid $33.0M operating cash use versus $65.6M provided YoY.

• ·Inventories increased $33.9M QoQ to $611.5M.
• ·Accounts receivable decreased $57.1M QoQ to $359.9M.
• ·Restructuring charges fell to $4.4M from $16.1M YoY.
• ·Capital expenditures $34.0M in Q1 FY2026 versus $56.2M YoY.
• ·Basic loss per share $(1.35) versus $(0.19) YoY.

06-05-2026

Prospect Hill Management, LLC filed a 13F-HR report disclosing $224,370,514 in total holdings across 14 positions as of March 31, 2026. The portfolio is heavily weighted toward technology stocks, with top holdings in Apple Inc. ($128,284,754, 505,476 shares) and Tesla Inc. ($37,403,998, 100,616 shares). Other significant positions include Amazon.com Inc. ($10,984,785), Alphabet Inc. Class A ($8,014,297) and Class C ($8,611,537).

• ·Filing submitted on May 6, 2026, for period ending March 31, 2026
• ·All holdings reported with sole voting power (SH SOLE)

06-05-2026

For the quarter ended March 27, 2026, Fresh Del Monte Produce Inc reported net sales of $1,044.1 million, down 5% YoY from $1,098.4 million, with gross profit declining 3% to $89.0 million and operating income dropping 55% to $20.1 million primarily due to $20.0 million in asset impairments and higher SG&A expenses. Net income fell to $10.7 million from $31.9 million YoY. However, the company completed the acquisition of select assets from Del Monte Foods for $307.7 million net of cash acquired, contributing to total assets rising 11% QoQ to $3,402.4 million and cash increasing to $66.3 million from $35.7 million QoQ.

• ·Dividends declared per ordinary share remained flat at $0.30 for Q1 2026.
• ·Asset impairments of $16.1 million in cash flow adjustments for Q1 2026.
• ·Proceeds from debt of $266.9 million in financing activities, likely related to the acquisition.
• ·Net assets acquired from Del Monte Foods totaled $341.9 million.

06-05-2026

Royalty Pharma reported first quarter 2026 Portfolio Receipts of $925 million, up 10% YoY from $839 million, driven by 13% growth in Royalty Receipts to $887 million from strong performances in Tremfya (+679%), Voranigo (+140%), and Evrysdi (+51%). However, Royalty Receipts were partially offset by sharp declines including Promacta (-61%), Imbruvica (-17%), Tysabri (-3%), Xtandi (-3%), and Spinraza (-9%), while Milestones and other receipts fell 25% to $38 million. The company raised full-year 2026 Portfolio Receipts guidance to $3,325 million to $3,450 million (previously $3,275-$3,425 million), announced up to $1.25 billion in new royalty transactions including R&D co-funding with Johnson & Johnson and Teva, and generated net cash from operating activities of $718 million (+20% YoY).

• ·Non-cash impairment charges of $69 million recorded in Q1 2026 related to Tazverik following voluntary market withdrawal.
• ·Theravance Biopharma's Phase 3 CYPRESS study for ampreloxetine did not meet primary endpoint, leading to program wind-down.
• ·Capital Deployment of $528 million in Q1 2026, including acquisitions of financial royalty assets ($452 million).
• ·Payments for operating and professional costs decreased to $36 million in Q1 2026 from $102 million in Q1 2025.

06-05-2026

For Q1 2026 ended March 31, total revenue declined 56% YoY to $6,472 thousand amid sharp drop in operating revenue to $6,301 thousand from $14,818 thousand, while grant revenue improved to $171 thousand from ($73) thousand. Operating expenses fell 35% YoY to $134,977 thousand, leading to a narrower net loss of $117,504 thousand versus $202,487 thousand prior year and reduced operating cash use to $81,101 thousand from $131,957 thousand. Stockholders' equity stood at $1,024,769 thousand at quarter-end, down from $1,130,865 thousand at December 31, 2025.

• ·Operating revenue declined 57% YoY to $6,301 thousand.
• ·Research and development expenses decreased to $87,896 thousand from $129,634 thousand.
• ·Cash, cash equivalents and restricted cash decreased $88,741 thousand during the quarter to $665,180 thousand.
• ·Accrued expenses and other liabilities fell to $54,205 thousand from $70,230 thousand at December 31, 2025.

06-05-2026

Apollo Global Management reported first quarter 2026 results ended March 31, 2026, achieving record fee-related earnings and assets under management of $1.03 trillion, marking a significant milestone. The company declared a cash dividend of $0.5625 per share on common stock payable May 29, 2026, and $0.8438 per share on mandatory convertible preferred stock payable July 31, 2026. No declines or flat metrics were disclosed in the release.

• ·Conference call held May 6, 2026 at 8:30 a.m. Eastern Time; replay available on ir.apollo.com.
• ·Common stock dividend record date: May 19, 2026; payment date: May 29, 2026.
• ·Mandatory convertible preferred stock dividend record date: July 15, 2026; payment date: July 31, 2026.
• ·Full Q1 2026 results presentation available on ir.apollo.com.

06-05-2026

Amphenol Corporation (NYSE: APH) announced the pricing of €600 million aggregate principal amount of 3.375% senior notes due 2029 and €500 million aggregate principal amount of 3.875% senior notes due 2034, with closing expected on May 12, 2026, subject to customary conditions. Net proceeds will be used to repay borrowings under its U.S. commercial paper program and 364-day unsecured delayed draw term loan credit agreement, and for general corporate purposes. Barclays Bank PLC, Citigroup Global Markets Limited, Commerzbank Aktiengesellschaft, and HSBC Bank plc are the joint book-running managers.

• ·Pricing announced on May 5, 2026
• ·Notes offered pursuant to effective shelf registration statement on file with the SEC
• ·Prospectus supplement to be filed with the SEC

06-05-2026

Cryder Capital Partners LLP disclosed 10 equity holdings totaling $1,531,097,190 as of March 31, 2026, in its 13F-HR filing submitted on May 6, 2026. The portfolio consists entirely of sole voting power positions with no shared or other voting authority reported. Key holdings include HCA Healthcare Inc at $215,061,079 (454,444 shares), Thermo Fisher Scientific Inc at $185,150,012 (376,681 shares), and Microsoft Corp at $177,203,340 (478,708 shares).

• ·All positions held with sole voting authority (SH SOLE); no shared or other voting authority reported.
• ·Firm address: 10 Cork Street, London X0 W1S 3NP.

06-05-2026

ITT reported Q1 2026 revenue of $1,211.9 million, up 32.7% (10.9% organic) versus prior year, driven by the SPX FLOW acquisition and organic growth across all segments including 17.5% organic in Connect & Control Technologies and 12.2% in Flow Technologies; adjusted EPS rose 25.3% to $1.98 with adjusted operating margin expanding 130 bps to 20.3%. However, reported EPS declined 33.1% to $0.89, operating income fell 6.4% to $141.2 million with margin contracting 480 bps to 11.7%, and free cash flow dropped 82.0% to $13.8 million due to acquisition-related payments and higher working capital. The company initiated full-year 2026 adjusted EPS guidance of $7.70 to $8.00 (up 9% at midpoint) and organic revenue growth of 4% to 6%, reflecting SPX FLOW integration.

• ·Flow Technologies adjusted operating margin increased 100 bps to unstated value (reported margin 15.3%, down 380 bps); Motion Technologies operating margin 21.0% (+150 bps); Connect & Control Technologies operating margin 17.7% (+240 bps).
• ·Full-year 2026 guidance: total revenue growth 36-38%, operating margin 12.4-13.3%, free cash flow $540-580 million (10-11% margin).
• ·Quarterly dividend of $0.386 per share payable July 6, 2026 to shareholders of record June 8, 2026.
• ·Total book-to-bill remains well above 1.

06-05-2026

Hagerty reported Q1 2026 written premium growth of over 18% driven by record new business, reaching 1.8 million policies in force with 89% retention, while on track for 15-16% full-year written premium growth and a goal of 3 million policies by 2030. Broad Arrow Auctions achieved a record $111 million in sales at The Amelia (50% higher than prior year) with 92% sell-through. Reported revenue and net income appear different from 2025 due to a shift to 100% quota share accounting, though it boosts underwriting profits and investment income by 25%; the company notes increased claims in driving season and ongoing investments in growth.

• ·Partnerships with nine of the top 10 US auto insurers.
• ·Over half of State Farm’s 525,000 policies expected on Hagerty platform by 2026 year-end.
• ·Rollout of Liberty/Safeco partnership in 2027.
• ·Expanded underwriting to vehicles from 1990s, 2000s, and brand-new models like Porsche 911.

06-05-2026

Johnson Controls International plc reported strong Q2 FY26 results with net sales up 8% to $6.1 billion (organic +6%) and adjusted EPS of $1.19, reflecting 45% growth. Orders surged 30% organically and backlog hit a record $20.0 billion (+26% organically), driven by data center demand; all segments showed sales growth and margin expansion, though EMEA organic sales rose only 1% due to Middle East disruptions. The company raised FY26 guidance to ~6% organic sales growth and ~$4.85 adjusted EPS.

• ·Americas adjusted Segment EBITA margin 19.5% (+100 bp YoY)
• ·EMEA Segment EBIT margin 14.0% (+430 bp YoY)
• ·APAC adjusted Segment EBITA margin 19.8% (+350 bp YoY)
• ·Corporate adjusted expense $102M (-24% YoY)
• ·Q3 FY26 guidance: adjusted EPS ~$1.28
• ·FY26 adjusted free cash flow conversion ~100%

06-05-2026

BioCryst reported Q1 2026 ORLADEYO net revenue of $148.3 million, up 11% YoY (+21% on comparable basis excluding European revenue), driving total revenues to $156.4 million, while achieving non-GAAP operating profit of $54.2 million. However, GAAP operating loss was $701.6 million due to a $697.8 million non-cash acquired IPRD expense from the January Astria Therapeutics acquisition, and the company discontinued avoralstat development. Cash stood at $260.8 million (pro-forma $330.8 million post $70 million navenibart European licensing upfront), with FY2026 ORLADEYO revenue guidance unchanged at $625-645 million.

• ·Patient enrollment in ALPHA-ORBIT on track for completion by end of June 2026, supporting US regulatory filing by end of 2027.
• ·Began dosing in Part 4 of BCX17725 Phase 1 trial; data expected by end of 2026.
• ·FY2026 guidance: Total revenue $635-660M; non-GAAP opex (excl. SBC, restructuring, transaction) $450-470M.
• ·Tiered royalties on navenibart European net sales: 18%-30%.

06-05-2026

Madrigal Pharmaceuticals reported first-quarter 2026 Rezdiffra net sales of $311.3 million, up 127% YoY from $137.3 million, with more than 42,250 patients on therapy, a 2.5x increase from Q1 2025, reflecting strong adoption. However, operating expenses surged 86.6% to $404.1 million from $216.6 million, driven by $54.3 million in upfront business development costs and commercial investments, leading to a net loss of $94.4 million versus $73.2 million prior year. Cash and equivalents totaled $817.9 million as of March 31, 2026, down from $988.6 million at December 31, 2025.

• ·Licensing agreement with Arrowhead for global rights to ARO-PNPLA3 targeting PNPLA3 mutation in ~30% of F2-F3 MASH patients.
• ·ARO-PNPLA3 Phase 1 showed up to 46% liver fat reduction at 12 weeks.
• ·Rezdiffra IP protection expected into 2045.
• ·MGL-2086 Phase 1 on track for 2Q26 initiation; ervogastat/resmetirom DDI study for 4Q26.
• ·Conference call held May 6, 2026 at 8 a.m. EDT.

06-05-2026

EyePoint Pharmaceuticals reported Q1 2026 net revenue of $0.7 million, a 97% YoY decline from $24.5 million primarily due to recognition of deferred YUTIQ license revenue in the prior year, while operating expenses rose 20% to $87.9 million driven by Phase 3 DURAVYU trials, resulting in a net loss of $84.8 million ($0.99 per share) versus $45.2 million ($0.65 per share) last year. Cash and investments stood at $223 million as of March 31, 2026, down from $306 million at year-end 2025 but providing runway into Q4 2027. Clinical progress remains strong with Phase 3 wet AMD trials (LUGANO/LUCIA) on track for mid-2026 topline data and DME trials (COMO/CAPRI) over one-third enrolled, targeting Q3 2026 completion.

• ·Wet AMD Phase 3 trials enrolled over 900 patients; all active treatment arm patients reached Week 32, over 35% reached Week 56.
• ·DME Phase 3 trials expected to enroll approximately 480 patients; ex-US sites activated.
• ·Interim masked Phase 3 safety data consistent with prior trials, no safety signals.

06-05-2026

Tonix Pharmaceuticals Holding Corp. (TNXP) announced an agreement effective May 1, 2026, with a leading group purchasing organization (GPO) providing coverage for TONMYA® to approximately 35 million U.S. commercially insured lives, representing 20% of the ~177 million commercial lives. TONMYA is already covered under Medicaid in 38 states, reaching ~55 million beneficiaries or 73% of ~75 million Medicaid lives. This milestone expands access to the first FDA-approved fibromyalgia treatment in over 15 years, commercially launched in November 2025.

• ·TONMYA FDA approved on August 15, 2025; first new fibromyalgia treatment in >15 years.
• ·U.S. patents for TONMYA provide market exclusivity until 2034/2035.
• ·Commercially launched November 2025.